文献速递膀胱癌与上尿路尿路上皮癌

[18F]FDG-PET/CT 优化高危上尿路尿路上皮癌分期与治疗选择

[18F]fluorodeoxyglucose PET/CT refines staging and treatment selection in high-risk upper tract urothelial carcinoma.
PubMed 文献 · BJU Int · 2026-10-13

该研究为单中心连续配对影像队列,纳入 2013 至 2025 年疑似高危上尿路尿路上皮癌(UTUC)患者 203 例,评估 [18F]FDG-PET/CT 在增强 CT(CECT)基础上的增量价值。结果显示 PET/CT 使 45 例(22%)发生分期迁移、43 例(21%)治疗改变,在 CECT 可疑淋巴结者中分期迁移更常见(OR 3.4,95%CI 1.6-7.3)。

要点

  • PET/CT 在 CECT 基础上使 22% 患者分期迁移,以升期为主。
  • PET/CT 导致 21% 患者治疗方案修改,支持选择性用于初始分期。
  • CECT 可疑淋巴结者分期迁移风险更高(OR 3.4)。

核心结论

  • [18F]FDG-PET/CT 在高危 UTUC 初始分期中可提供超越 CECT 的可操作分期信息,支持选择性使用以优化治疗选择。

研究设计与样本

  • 单中心连续配对影像队列研究,2013 至 2025 年纳入 203 例疑似高危 UTUC 并同时接受 CECT 与 [18F]FDG-PET/CT 初始分期的患者。

主要发现

  • 203 例中 45 例(22%)发生分期迁移,主要为升期 39 例(19%),其中区域淋巴结升期 19 例(9.4%)、远处转移升期 22 例(11%),两者兼有 2 例。
  • [18F]FDG-PET/CT 使 43 例(21%)治疗发生修改。
  • CECT 可疑淋巴结者分期迁移更常见(OR 3.4,95%CI 1.6-7.3)。
  • 62 例有组织病理学验证者中,PET/CT 对淋巴结转移的敏感性高于 CECT(74% vs 33%),特异性相近(89% vs 86%)。

关键数值与推荐

  • 分期迁移定义:非转移性与转移性疾病之间的转换及其对多学科治疗推荐的影响。
  • CECT 可疑淋巴结者分期迁移的 OR 为 3.4(95%CI 1.6-7.3)。
  • 病理验证亚组中 PET/CT 与 CECT 淋巴结转移敏感性分别为 74% 与 33%,特异性分别为 89% 与 86%。

临床怎么用

  • 对疑似高危 UTUC 初始分期可在 CECT 基础上选择性加做 [18F]FDG-PET/CT,尤其 CECT 见可疑淋巴结者,以细化分期并指导治疗选择。

局限性

  • 回顾性单中心设计,病理确认不完整,主要因新辅助治疗及转移性疾病未行手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the incremental clinical value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) beyond contrast-enhanced computed tomography (CECT) for primary staging of suspected high-risk upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: We conducted a consecutive paired-imaging cohort study of patients with suspected high-risk UTUC undergoing primary staging with both CECT and [18F]FDG-PET/CT at a tertiary cancer centre between 2013 and 2025. The primary outcome was clinically relevant stage migration, defined as a transition between non-metastatic and metastatic disease, and its impact on multidisciplinary treatment recommendation. Secondary outcomes included diagnostic performance in cases with histopathological verification. RESULTS: Among 203 patients, [18F]FDG-PET/CT resulted in stage migration in 45 (22%), predominantly through upstaging (39 patients [19%]), comprising regional nodal upstaging in 19 patients (9.4%) and distant metastatic upstaging in 22 (11%), with both occurring in two patients. [18F]FDG-PET/CT led to treatment modification in 43 patients (21%). Stage migration was more frequent in the presence of CECT-suspicious lymph nodes (odds ratio 3.4, 95% confidence interval 1.6-7.3). Among the 62 patients with histopathological verification, [18F]FDG-PET/CT demonstrated significantly higher sensitivity for nodal metastases than CECT (74% vs 33%) with similar specificity (89% vs 86%). Limitations include the retrospective single-centre design and incomplete pathological confirmation, mostly due to neoadjuvant treatment and omission of surgery in metastatic disease. CONCLUSION: [18F]FDG-PET/CT provides actionable staging information beyond CECT in high-risk UTUC, leading to treatment modification in one in five patients and in half of those with CECT-suspicious nodal disease. These findings support selective use of [18F]FDG-PET/CT in primary staging to refine treatment selection.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lijnen RAG, Ringia JB, Hendricksen K, et al. [18F]fluorodeoxyglucose PET/CT refines staging and treatment selection in high-risk upper tract urothelial carcinoma. BJU Int. 2026. PMID: 42870369. doi:10.1111/bju.70483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。